- Previous Close
4.0800 - Open
4.0600 - Bid 3.9700 x 100
- Ask 4.2100 x 100
- Day's Range
4.0300 - 4.4400 - 52 Week Range
1.8200 - 8.7500 - Volume
110,381 - Avg. Volume
149,065 - Market Cap (intraday)
208.278M - Beta (5Y Monthly) 0.26
- PE Ratio (TTM)
-- - EPS (TTM)
-1.2900 - Earnings Date Mar 20, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.57
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
www.ranitherapeutics.comRecent News: RANI
Performance Overview: RANI
Trailing total returns as of 6/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RANI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RANI
Valuation Measures
Market Cap
106.00M
Enterprise Value
101.83M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
14.33
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-53.03%
Return on Equity (ttm)
-172.96%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-33.08M
Diluted EPS (ttm)
-1.2900
Balance Sheet and Cash Flow
Total Cash (mrq)
39.58M
Total Debt/Equity (mrq)
243.62%
Levered Free Cash Flow (ttm)
-24.63M